Advertisement

Mycopathologia

, Volume 182, Issue 5–6, pp 471–485 | Cite as

In Vitro Antifungal Susceptibility of Oral Candida Isolates from Patients Suffering from Caries and Chronic Periodontitis

  • Janire De-la-Torre
  • María Esther Ortiz-Samperio
  • Cristina Marcos-Arias
  • Xabier Marichalar-Mendia
  • Elena Eraso
  • María Ángeles Echebarria-Goicouria
  • José Manuel Aguirre-Urizar
  • Guillermo Quindós
Article

Abstract

Caries and chronic periodontitis are common oral diseases where a higher Candida colonization is reported. Antifungal agents could be adjuvant drugs for the therapy of both clinical conditions. The aim of the current study has been to evaluate the in vitro activities of conventional and new antifungal drugs against oral Candida isolates from patients suffering from caries and/or chronic periodontitis. In vitro activities of amphotericin B, fluconazole, itraconazole, miconazole, nystatin, posaconazole and voriconazole against 126 oral Candida isolates (75 Candida albicans, 18 Candida parapsilosis, 11 Candida dubliniensis, six Candida guilliermondii, five Candida lipolytica, five Candida glabrata, four Candida tropicalis and two Candida krusei) from 61 patients were tested by the CLSI M27-A3 method. Most antifungal drugs were highly active, and resistance was observed in less than 5% of tested isolates. Miconazole was the most active antifungal drug, being more than 98% of isolates susceptible. Fluconazole, itraconazole, and the new triazoles, posaconazole and voriconazole, were also very active. Miconazole, fluconazole and voriconazole have excellent in vitro activities against all Candida isolates and could represent suitable treatment for a hypothetically adjunctive therapy of caries and chronic periodontitis.

Keywords

Antifungal susceptibility Oral Candida Caries Chronic periodontitis Amphotericin B Nystatin Miconazole Fluconazole Itraconazole Voriconazole Posaconazole 

Notes

Acknowledgements

Cristina Marcos-Arias is recipient of a grant from Fundación ONCE (« Oportunidad al Talento ») and Fondo Social Europeo. Elena Eraso and Guillermo Quindós have received grant support from Consejería de Educación, Universidades e Investigación (GIC15 78-IT-990-16 and GIC12 210-IT-809-13) and Departamento de Industria, Comercio y Turismo (S-PE13UN121) of Gobierno Vasco-Eusko Jaurlaritza, Fondo de Investigación Sanitaria (FIS PI11/00203), and UPV/EHU (UFI 11/25). Xabier Marichalar-Mendia, María Ángeles Echebarria-Goicouria, and José Manuel Aguirre-Urizar have received grant support from Consejería de Educación, Universidades e Investigación (GIC12 IT-809-13) of Gobierno Vasco-Eusko Jaurlaritza.

Compliance with Ethical Standards

Conflict of interest

In the past 5 years, Elena Eraso has received grant support from Astellas Pharma, and Pfizer SLU. Guillermo Quindós has received grant support from Astellas Pharma, Gilead Sciences, Pfizer SLU, Schering Plough and Merck Sharp and Dohme. He has been an advisor/consultant to Merck Sharp and Dohme, and has been paid for talks on behalf of Abbvie, Astellas Pharma, Esteve Hospital, Gilead Sciences, Merck Sharp and Dohme, Pfizer SLU, and Schering Plough. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

References

  1. 1.
    Metwalli KH, Khan SA, Krom BP, Jabra-Rizk MA. Streptococcus mutans, Candida albicans, and the human mouth: a sticky situation. PLoS Pathog. 2013;9:e1003616.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Gangula P, Ravella K, Chukkapalli S. Polybacterial periodontal pathogens alter vascular and gut BH4/nNOS/NRF2-phase II enzyme expression. PLoS One. 2015;10:e0129885.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Yang F, Zeng X, Ning K. Saliva microbiomes distinguish caries-active from healthy human populations. ISME J. 2012;6:1–10.CrossRefPubMedGoogle Scholar
  4. 4.
    Ge X, Rodriguez R, Trinh M, Gunsolley J, Xu P. Oral microbiome of deep and shallow dental pockets in chronic periodontitis. PLoS One. 2013;8:e65520.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Krom BP, Kidwai S, Ten Cate JM. Candida and other fungal species: forgotten players of healthy oral microbiota. J Dent Res. 2014;93:445–51.CrossRefPubMedGoogle Scholar
  6. 6.
    Raja M, Hannan A, Ali K. Association of oral candidal carriage with dental caries in children. Caries Res. 2010;44:272–6.CrossRefPubMedGoogle Scholar
  7. 7.
    De-la-Torre J, Marichalar-Mendia X, Varona-Barquin A, Marcos-Arias C, Eraso E, Aguirre-Urizar JM, Quindós G. Caries and Candida colonisation in adult patients in Basque Country (Spain). Mycoses. 2016;59:234–40.CrossRefGoogle Scholar
  8. 8.
    Meurman JH, Parnanen P, Seneviratne CJ, Samaranayake LP, Saarinen AM, Kari K. Prevalence and antifungal drug sensitivity of non-albicans Candida in oral rinse samples of self-caring elderly. Gerodontology. 2011;28:246–52.CrossRefPubMedGoogle Scholar
  9. 9.
    Urzua B, Hermosilla G, Gamonal J. Yeast diversity in the oral microbiota of subjects with periodontitis: Candida albicans and Candida dubliniensis colonize the periodontal pockets. Med Mycol. 2008;46:783–93.CrossRefPubMedGoogle Scholar
  10. 10.
    Zijnge V, van Leeuwen MB, Degener JE. Oral biofilm architecture on natural teeth. PLoS One. 2010;5:e9321.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Sardi JC, Duque C, Mariano FS, Marques MR, Hofling JF, Goncalves RB. Adhesion and invasion of Candida albicans from periodontal pockets of patients with chronic periodontitis and diabetes to gingival human fibroblasts. Med Mycol. 2012;50:43–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Sardi JC, Duque C, Mariano FS, Peixoto IT, Hofling JF, Goncalves RB. Candida spp. in periodontal disease: a brief review. J Oral Sci. 2010;52:177–85.CrossRefPubMedGoogle Scholar
  13. 13.
    Sardi JC, Almeida AM, Mendes Giannini MJ. New antimicrobial therapies used against fungi present in subgingival sites–a brief review. Arch Oral Biol. 2011;56:951–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Williams DW, Lewis MA. Isolation and identification of Candida from the oral cavity. Oral Dis. 2000;6:3–11.CrossRefPubMedGoogle Scholar
  15. 15.
    Byadarahally Raju S, Rajappa S. Isolation and identification of Candida from the oral cavity. ISRN Dent. 2011;2011:487921.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Premkumar J, Ramani P, Chandrasekar T, Natesan A, Premkumar P. Detection of species diversity in oral Candida colonization and anti-fungal susceptibility among non-oral habit adult diabetic patients. J Nat Sci Biol Med. 2014;5:148–54.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Matic Petrovic S, Cimbaljevic M, Radunovic M, Kuzmanovic Pficer J, Jotic A, Pucar A. Detection and sampling methods for isolation of Candida spp. from oral cavities in diabetics and non-diabetics. Braz Oral Res. 2015;. doi: 10.1590/1807-3107BOR-2015.vol29.0077.PubMedGoogle Scholar
  18. 18.
    Eraso E, Moragues MD, Villar-Vidal M, Sahand IH, González-Gómez N, Pontón J, Quindós G. Evaluation of the new chromogenic medium Candida ID 2 for isolation and identification of Candida albicans and other medically important Candida species. J Clin Microbiol. 2006;44:3340–5.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Romeo O, Criseo G. First molecular method for discriminating between Candida africana, Candida albicans, and Candida dubliniensis by using hwp1 gene. Diagn Microbiol Infect Dis. 2008;62:230–3.CrossRefPubMedGoogle Scholar
  20. 20.
    Pravin Charles MV, Kali A, Joseph NM. Performance of chromogenic media for Candida in rapid presumptive identification of Candida species from clinical materials. Pharmacogn Res. 2015;7(Suppl 1):S69–73.Google Scholar
  21. 21.
    Blignaut E, van Heerden WF. Molecular and histological association between Candida albicans from oral soft tissue and carious dentine of HIV-positive children. Mycopathologia. 2015;180:193–201.CrossRefPubMedGoogle Scholar
  22. 22.
    Bravo Pérez M, Casals Peidró E, Cortés Marticorena FJ, Llodra Calvo JC. Encuesta de salud oral en España 2005. RCOE. 2006;11:409–56.Google Scholar
  23. 23.
    Becker T, Levin L, Shochat T, Einy S. How much does the DMFT index underestimate the need for restorative care? J Dent Educ. 2007;71:677–81.PubMedGoogle Scholar
  24. 24.
    Jiang Q, Yu M, Min Z, Yi A, Chen D, Zhang Q. AP-PCR detection of Streptococcus mutans and Streptococcus sobrinus in caries-free and caries-active subjects. Mol Cell Biochem. 2012;365:159–64.CrossRefPubMedGoogle Scholar
  25. 25.
    Kassebaum NJ, Bernabe E, Dahiya M, Bhandari B, Murray CJ, Marcenes W. Global burden of untreated caries: a systematic review and metaregression. J Dent Res. 2015;94:650–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Savage A, Eaton KA, Moles DR, Needleman I. A systematic review of definitions of periodontitis and methods that have been used to identify this disease. J Clin Periodontol. 2009;36:458–67.CrossRefPubMedGoogle Scholar
  27. 27.
    Canabarro A, Valle C, Farias MR, Santos FB, Lazera M, Wanke B. Association of subgingival colonization of Candida albicans and other yeasts with severity of chronic periodontitis. J Periodontal Res. 2013;48:428–32.CrossRefPubMedGoogle Scholar
  28. 28.
    Holtfreter B, Albandar JM, Dietrich T. Standards for reporting chronic periodontitis prevalence and severity in epidemiologic studies: Proposed standards from the joint EU/USA periodontal epidemiology working group. J Clin Periodontol. 2015;42:407–12.CrossRefPubMedGoogle Scholar
  29. 29.
    Smiley CJ, Tracy SL, Abt E, Michalowicz BS, John MT, Gunsolley J, Cobb CM, Rossmann J, Harrel SK, Forrest JL, Hujoel PP, Noraian KW, Greenwell H, Frantsve-Hawley J, Estrich C, Hanson N. Evidence-based clinical practice guideline on the nonsurgical treatment of chronic periodontitis by means of scaling and root planing with or without adjuncts. J Am Dent Assoc. 2015;146:525–35.CrossRefPubMedGoogle Scholar
  30. 30.
    Clinical and Laboratory Standards Institute. Clinical and laboratory standards institute. reference method for broth dilution antifungal susceptibility testing for years; approved standard, 3rd ed. CLSI document M27-S3. 2008.Google Scholar
  31. 31.
    Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing for yeasts, fourth informational supplement. CLSI document M27-S4. 2012.Google Scholar
  32. 32.
    Pfaller MA, Messer SA, Jones RN, Castanheira M. Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010–2012). J Antibiot. 2015;68:556–61.CrossRefPubMedGoogle Scholar
  33. 33.
    Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62:e1–50.CrossRefPubMedGoogle Scholar
  34. 34.
    Pfaller MA, Diekema DJ. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol. 2012;50:2846–56.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Sanchez Vargas LO, Eraso E, Carrillo-Munoz AJ, Aguirre JM, Gaitan-Cepeda LA, Quindos G. In vitro activity of voriconazole against Mexican oral yeast isolates. Mycoses. 2010;53:200–3.CrossRefPubMedGoogle Scholar
  36. 36.
    Patil S, Rao RS, Majumdar B, Anil S. Clinical appearance of oral Candida infection and therapeutic strategies. Front Microbiol. 2015;6:1391.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Waltimo TM, Orstavik D, Meurman JH, Samaranayake LP, Haapasalo MP. In vitro susceptibility of Candida albicans isolates from apical and marginal periodontitis to common antifungal agents. Oral Microbiol Immunol. 2000;15:245–8.CrossRefPubMedGoogle Scholar
  38. 38.
    Kamikawa Y, Mori Y, Nagayama T. Frequency of clinically isolated strains of oral Candida species at Kagoshima University Hospital, Japan, and their susceptibility to antifungal drugs in 2006–2007 and 2012–2013. BMC Oral Health. 2014;14:14-6831-14-14.CrossRefGoogle Scholar
  39. 39.
    Isham N, Ghannoum MA. Antifungal activity of miconazole against recent Candida strains. Mycoses. 2010;53:434–7.CrossRefPubMedGoogle Scholar
  40. 40.
    Rautemaa R, Ramage G. Oral candidosis–clinical challenges of a biofilm disease. Crit Rev Microbiol. 2011;37:328–36.CrossRefPubMedGoogle Scholar
  41. 41.
    Bensadoun RJ, Daoud J, El Gueddari B. Comparison of the efficacy and safety of miconazole 50-mg mucoadhesive buccal tablets with miconazole 500-mg gel in the treatment of oropharyngeal candidiasis: a prospective, randomized, single-blind, multicenter, comparative, phase III trial in patients treated with radiotherapy for head and neck cancer. Cancer. 2008;112:204–11.CrossRefPubMedGoogle Scholar
  42. 42.
    Collins CD, Cookinham S, Smith J. Management of oropharyngeal candidiasis with localized oral miconazole therapy: efficacy, safety, and patient acceptability. Patient Prefer Adherence. 2011;5:369–74.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    De Cremer K, Lanckacker E, Cools TL. Artemisinins, new miconazole potentiators resulting in increased activity against Candida albicans biofilms. Antimicrob Agents Chemother. 2015;59:421–6.CrossRefPubMedGoogle Scholar
  44. 44.
    Aljaeid BM, Hosny KM. Miconazole-loaded solid lipid nanoparticles: Formulation and evaluation of a novel formula with high bioavailability and antifungal activity. Int J Nanomed. 2016;11:441–7.CrossRefGoogle Scholar
  45. 45.
    Salim N, Moore C, Silikas N, Satterthwaite J, Rautemaa R. Chlorhexidine is a highly effective topical broad-spectrum agent against Candida spp. Int J Antimicrob Agents. 2013;41:65–9.CrossRefPubMedGoogle Scholar
  46. 46.
    Razzaghi-Abyaneh M, Sadeghi G, Zeinali E. Species distribution and antifungal susceptibility of Candida spp. isolated from superficial candidiasis in outpatients in Iran. J Mycol Med. 2014;24:e43–50.CrossRefPubMedGoogle Scholar
  47. 47.
    Jewtuchowicz VM, Brusca MI, Mujica MT. Subgingival distribution of yeast and their antifungal susceptibility in immunocompetent subjects with and without dental devices. Acta Odontol Latinoam. 2007;20:17–22.PubMedGoogle Scholar
  48. 48.
    Brito GN, Inocencio AC, Querido SM, Jorge AO, Koga-Ito CY. In vitro antifungal susceptibility of Candida spp. oral isolates from HIV-positive patients and control individuals. Braz Oral Res. 2011;25:28–33.CrossRefPubMedGoogle Scholar
  49. 49.
    Ito CY, de Paiva Martins CA, Loberto JC, dos Santos SS, Jorge AO. In vitro antifungal susceptibility of Candida spp. isolates from patients with chronic periodontitis and from control patients. Braz Oral Res. 2004;18:80–4.CrossRefPubMedGoogle Scholar
  50. 50.
    Moran GP, Sullivan DJ, Henman MC. Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro. Antimicrob Agents Chemother. 1997;41:617–23.PubMedPubMedCentralGoogle Scholar
  51. 51.
    Marcos-Arias C, Eraso E, Madariaga L, Carrillo-Muñoz AJ, Quindos G. In vitro activities of new triazole antifungal agents, posaconazole and voriconazole, against oral Candida isolates from patients suffering from denture stomatitis. Mycopathologia. 2012;173:35–46.CrossRefPubMedGoogle Scholar
  52. 52.
    Pfaller MA, Rhomberg PR, Messer SA, Jones RN, Castanheira M. Isavuconazole, micafungin, and 8 comparator antifungal agents susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values. Diagn Microbiol Infect Dis. 2015;82:303–13.CrossRefPubMedGoogle Scholar
  53. 53.
    Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ. Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program. J Clin Microbiol. 2008;46(2):551–9.CrossRefPubMedGoogle Scholar
  54. 54.
    Smiline GA, Pandi SK, Hariprasad P, Raguraman R. A preliminary study on the screening of emerging drug resistance among the caries pathogens isolated from carious dentine. Indian J Dent Res. 2012;23:26–30.CrossRefPubMedGoogle Scholar
  55. 55.
    Niimi M, Firth NA, Cannon RD. Antifungal drug resistance of oral fungi. Odontology. 2010;98:15–25.CrossRefPubMedGoogle Scholar
  56. 56.
    Arikan S, Ostrosky-Zeichner L, Lozano-Chiu M. In vitro activity of nystatin compared with those of liposomal nystatin, amphotericin B, and fluconazole against clinical Candida isolates. J Clin Microbiol. 2002;40:1406–12.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Quindós G, Carrillo-Muñoz AJ, Ruesga MT, Alonso-Vargas R, Miranda Y, Tur-Tur C, Rubio M, Wallace TL, Cossum PA, Martín-Mazuelos E, Cisterna R, Pontón J. In vitro activity of a new liposomal nystatin formulation against opportunistic fungal pathogens. Eur J Clin Microbiol Infect Dis. 2000;19:645–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2017

Authors and Affiliations

  • Janire De-la-Torre
    • 1
    • 2
  • María Esther Ortiz-Samperio
    • 1
  • Cristina Marcos-Arias
    • 1
  • Xabier Marichalar-Mendia
    • 2
  • Elena Eraso
    • 1
  • María Ángeles Echebarria-Goicouria
    • 2
  • José Manuel Aguirre-Urizar
    • 2
  • Guillermo Quindós
    • 1
  1. 1.Laboratorio de Micología Médica, Departamento de Inmunología, Microbiología y Parasitología, UFI 11/25, Facultad de Medicina y EnfermeríaUniversidad del País Vasco-Euskal Herriko UnibertsitateaBilbaoSpain
  2. 2.Unidad de Medicina Bucal, Servicio Clínica Odontológica, Departamento de Estomatología II, UFI 11/25, Facultad de Medicina y EnfermeríaUniversidad del País Vasco-Euskal Herriko UnibertsitateaBilbaoSpain

Personalised recommendations